275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)

Key Points

• This research aims to assess the clinical impact of minimal residual disease (MRD) testing on treatment decisions for non-small cell lung cancer (NSCLC).
• Evaluated the feasibility of MRD testing in a real-world clinical setting.
• Analyzed decision-making changes in treatment strategies based on MRD findings.
• Collected data on patient outcomes related to MRD assessment.
• MRD testing was found to be feasible in a clinical context.
• Significant changes in treatment decisions were observed following MRD assessment.
• MRD presence correlated with increased risk of relapse in NSCLC patients.